Popular Pre-Market Trades in US Stocks
AIxCrypto is down 7.14% in pre-market trading. Based on recent news,
<ol>
<li>
On March 16, AIxCrypto released its weekly business update. Co-CEO Jerry Wang introduced the company's recent developments and strategies in the update. This news raised market concerns about the company's future prospects, leading to a drop in stock price.
</li>
<li>
On March 16, AIxCrypto released its latest business update in Los Angeles. The update included the company's strategic exploration of infrastructure in the emerging AI agent economy. Investor reactions to this strategy were mixed, resulting in stock price fluctuations.
</li>
<li>
On March 16, the business update released by AIxCrypto mentioned that the company's strategic exploration of infrastructure in the emerging AI agent economy has attracted widespread market attention. Investors have doubts about the company's future strategic direction, leading to a decline in stock price. The AI industry has been volatile recently, and investors should exercise caution.
</li>
</ol>
Gauzy is down 7.10% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Top Gainers in Pre-Market Trading in US Stocks
Li Bang is up 161.89% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Artelo Biosciences is up 52.39% in pre-market trading. Based on recent key news:
<ol>
<li>
On March 18, Artelo Biosciences announced an agreement with Glaucoma UK and HSC R&amp;D to initiate a fully funded clinical study evaluating the effects of its synthetic cannabinoid ART27.13 in glaucoma patients. This news drove the stock price up by over 40%. Source: Reuters
</li>
<li>
On March 18, Artelo Biosciences plans to test its experimental cannabinoid drug ART27.13 in the UK for the treatment of glaucoma. The drug aims to lower intraocular pressure without psychoactive effects. This move expands the clinical application of the drug and further boosts market confidence. Source: Reuters
</li>
<li>
On March 18, a Vanderbilt report indicated that Artelo Biosciences is entering the $16.3 billion glaucoma market through fully funded clinical research, demonstrating its potential in the ophthalmology field. Source: Vanderbilt Report The biotechnology industry has been active recently, with significant capital inflow.
</li>
</ol>
YY is up 49.47% in pre-market trading. Based on recent key news:
<ol>
<li>
On March 18, YY Group announced a partnership with Arros AI aimed at enhancing its workforce platform. This move is seen as an important step for the company in terms of technological innovation and business expansion, driving a significant increase in stock price
</li>
<li>
On March 17, YY Group announced a strategic investment in Arros AI, which is a member of the NVIDIA Inception program. This investment is interpreted by the market as the company's proactive layout in the field of artificial intelligence, further boosting investor confidence.
</li>
<li>
On March 16, YY Group launched a robot pilot project in Las Vegas, planning to test robot applications in the hotel and security markets. This move demonstrates the company's exploration in emerging technology fields and enhances market expectations for its future growth. Innovation in the technology industry drives stock price fluctuations
</li>
</ol>

AIXC

GAUZ

AIxCrypto pre-market down 7.14%; Gauzy pre-market down 7.10%; Li Bang pre-market up 161.89%; Artelo Biosciences pre-market up 52.39%; YY pre-market up 49.47%

Pre-market hot trades in US stocks: AIxCrypto pre-market down 7.14%; Gauzy pre-market down 7.10%